Fig. 4From: Amyloid positron emission tomography and cerebrospinal fluid results from a crenezumab anti-amyloid-beta antibody double-blind, placebo-controlled, randomized phase II study in mild-to-moderate Alzheimer’s disease (BLAZE)Aβ(1–40) and Aβ(1–42) plasma concentrations. Mean (±SD) Aβ(1–40) and Aβ(1–42) plasma concentrations following low-dose SC or high-dose IV administration to patients with mild-to-moderate AD (weeks 1–69). Aβ beta-amyloid, AD Alzheimer’s Disease, IV intravenous, SC subcutaneous, SD standard deviationBack to article page